Close
Antimicrobial resistance (AMR) is a leading cause of mortality worldwide, yet the burden of AMR on mortality at the patient-level is difficult to determine.
Estimating the total number of deaths associated with AMR is important yet challenging, as modelling approaches have significant limitations. The AMR-DC study aims to calculate the total number of AMR-associated deaths in England in the years 2021, 2022 and 2023 by linking routinely collected death certification data and microbiological data.
The AMR-DC study is sponsored by University College London and funded by the Health Security Agency. Key collaborators include the British Society for Antimicrobial Chemotherapy (BSAC), NHS England, the UK Health Security Agency and the London School of Hygiene and Tropical Medicine.
All patients who had their death registered in England between 01/01/2021 and 31/12/2023 will be included in the study, except for patients under the National Data Opt Out. Eligible patients will be identified through the Civil Registrations of Death database which will be linked to the Hospital Episode Statistics database and to the Second Generation Surveillance System for microbiological results within 28 days of death. All data will be collected in a completely anonymised manner and will be held securely in the UCL Data Safe Haven.
- Study Aims
- To describe the burden and trend of AMR-associated mortality in England in the years 2021 through to 2023
- To establish a pathway for public health authorities for calculating AMR-associated deaths in England using routinely collected data
- Study Details
IRAS ID: 340243
REC Reference No: 24/NW/0084
CAG Reference Number: 24/CAG/0050
- Study Investigators
Dr Louis Grandjean
Principal Investigator
Dr Ioannis Baltas
Co-Principal Investigator